ArticleChinese journal of integrative medicine2026
Berberine Ameliorates Atherosclerosis by Promoting Mitochondrial Biogenesis via SIRT1/PGC-1α Signaling Pathway.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate berberine (BBR) promotes mitochondrial biogenesis via the silent mating type information regulation 2 homolog 1/peroxisome proliferator-activated receptor gamma coactivator 1 alpha (SIRT1/PGC-1α) signaling pathway to exert its anti-atherosclerosis effects.
methodsA total of 42 8-week-old AopE
resultsAfter BBR intervention, BBRM and BBRH groups significantly reduced blood lipid levels in mice (P<0.01), alleviated aortic plaque deposition, and improved mitochondrial damage (P<0.05 or P<0.01). Additionally, BBR significantly upregulated the mRNA and protein expressions of SIRT1, PGC-1α, Nrf1, and TFAM (P<0.05 or P<0.01). And the relative copy number of mtDNA increased in a dose-dependent manner (P<0.01). In the BBRH+EX527 group, aortic lesions and mitochondrial damage were exacerbated, with concurrent decreases in mRNA and protein expression levels (P<0.05 or P<0.01).
conclusionBBR promotes mitochondrial biogenesis, maintains mitochondrial function, and inhibits mitochondrial damage through the SIRT1/PGC-1α signaling pathway, thereby improving atherosclerosis.
Indexed as
Identifiers
42043671What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.